Exploring the role and clinical implications of proteasome inhibition in medulloblastoma

Clay M. Hoerig, Ashley S. Plant-Fox, Michelle D. Pulley, Kaijun Di, Daniela A. Bota

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Ubiquitin proteasome-mediated protein degradation has been implicated in posttranslational oncogenesis in medulloblastoma. Current research is evaluating the clinical implications of proteasome inhibition as a therapeutic target. In medulloblastoma cell lines, proteasome inhibitors induce apoptosis and inhibit cell proliferation via multiple pathways involving activation of caspase pathways, NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway inhibition, reduced AKT/mTOR pathway activity, and pro-apoptotic protein expression. Second-generation proteasome inhibitors demonstrate blood–brain barrier penetration while maintaining antitumor effect. This review summarizes the ubiquitin-proteasome system in the pathogenesis of medulloblastoma and the potential clinical implications.

Original languageEnglish (US)
Article numbere29168
JournalPediatric Blood and Cancer
Issue number10
StatePublished - Oct 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 Wiley Periodicals LLC


  • marizomib
  • medulloblastoma
  • proteasome
  • ubiquitin


Dive into the research topics of 'Exploring the role and clinical implications of proteasome inhibition in medulloblastoma'. Together they form a unique fingerprint.

Cite this